Mer­ck pre­views an ear­ly hit with Keytru­da com­bo for kid­ney can­cer, putting more pres­sure on ri­val Bris­tol-My­ers

Mer­ck ar­rived at ES­MO in style, fronting their ap­pear­ance in Mu­nich with pos­i­tive — and very ear­ly — com­bi­na­tion da­ta for their PD-1 check­point star Keytru­da in treat­ing front­line kid­ney can­cer.

Re­searchers com­bined Keytru­da with Pfiz­er’s In­ly­ta for KEYNOTE-426 and came away with an ear­ly win on both pro­gres­sion-free and over­all sur­vival, along with a key sec­ondary in beat­ing Su­tent in a head-to-head show­down.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.